Skip to main content
Daniel Lin, MD, Urology, Seattle, WA

DanielWeiLinMD

Urology Seattle, WA

Surgical Oncology

Professor of Urology, University of Washington

Dr. Lin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Lin's full profile

Already have an account?

  • Office

    1660 S Columbian Way
    Section of Urology 112gu
    Seattle, WA 98108
    Phone+1 206-764-2265
    Fax+1 206-764-2239

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Urologic Surgical Oncology, 2000 - 2001
  • University of Washington School of Medicine
    University of Washington School of Medicine1998 - 2000
  • University of Washington
    University of WashingtonResidency, Urology, 1994 - 2000
  • University of Washington School of Medicine
    University of Washington School of Medicine1996 - 1998
  • University of Washington
    University of WashingtonInternship, Surgery, 1994 - 1995
  • Vanderbilt University School of Medicine
    Vanderbilt University School of MedicineClass of 1994
  • Stanford University
    Stanford UniversityB.S, Biology, 1989

Certifications & Licensure

  • AK State Medical License
    AK State Medical License 2022 - 2026
  • MT State Medical License
    MT State Medical License 2022 - 2026
  • WA State Medical License
    WA State Medical License 1997 - 2026
  • NY State Medical License
    NY State Medical License 2000 - 2002
  • American Board of Urology Urology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2012-2014
  • America's Top Doctors for Cancer Castle Connolly, 2011-2013
  • AUA Leadership Program American Urological Association, 2010
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Re: Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.  
    Lin DW, Journal of Urology
  • Treatment of Metastatic Prostate Cancer – How Urologists should Sequence Available Agents.  
    Mostaghel EA and Lin DW, AUA Update Series
  • Is Pre-diagnosis PSA Velocity Predictive of the Risk of Death from Prostate Cancer Following Radical Prostatectomy?  
    Lin DW and Lange PH, Nature Clinical Practice Urology 1: 66
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Prostate cancer ≤ 2 cells from the surgical margin predicts biochemical recurrence.
    Izard JP, True LD, May PC, Ellis WJ, Lange PH, Lin DW, and Wright JL, Journal of Urology 187 (4 suppl): 1641A
  • Transurethral Needle Ablation of the Prostate for Treatment of Benign Prostatic Hyperplasia: the University of Washington Experience.
    Lin DW, Ellis WJ, American Urological Association
  • Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) in Bone Marrow Aspirates Following Radical Prostatectomy with Extended Follow-up.
    Lin DW, Ellis WJ, Arfman EW, Sohn A, Corey E, Lange PH, Vessella RL, American Urological Association
  • Join now to see all

Lectures

  • Beyond PSA: Utility of Novel Tumor Markers in the Setting of Elevated PSA. 
    American Urological Association 2008 Annual Meeting, Orlando, FL
  • Adjuvant Chemohormonal Therapy in High Risk Prostate Cancer: a Point-Counterpoint Debate. 
    Northwest Urological Society Annual Meeting, Spokane, WA
  • Progress and Promise in Prostate Cancer Research. 
    VA R&D Research Colloquium, Seattle, WA
  • Join now to see all

Press Mentions

  • Why Men Should Be Screened for the ‘Breast Cancer Gene’
    Why Men Should Be Screened for the ‘Breast Cancer Gene’August 7th, 2024
  • SCCA’s Immunotherapy Leaders Featured at the American Society of Clinical Oncology (ASCO) Annual Meeting
    SCCA’s Immunotherapy Leaders Featured at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 31st, 2018
  • Popular Prostate Cancer Therapy Is Short, Intense and Unproven
    Popular Prostate Cancer Therapy Is Short, Intense and UnprovenMarch 20th, 2017
  • Join now to see all

Grant Support

  • In Vivo Effects Of Sulforaphane Supplementation On Normal Human ProstateNational Cancer Institute2009–2011
  • In Vivo Molecular Effects Of Prostatic COX-2 InhibitionNational Institute Of Diabetes And Digestive And Kidney Diseases2003–2007

Committees

  • Member, Castration-resistant Prostate Cancer Guidelines Panel, AUA 2015 - Present

Professional Memberships